Radiation treatment drug granted fast track status

Cleveland Biolabs' acute radiation syndrome drug, CBLB502, has received Fast Track status from the FDA. The drug, which would be used to treat patients who have been exposed to radiation from nuclear weapons or dirty bombs, completed Phase I testing in 2008. Release

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.